Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc

CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.

Exhibit 10.30

February 25, 2022

Neurocrine Biosciences, Inc.

12780 El Camino Real

San Diego, California

92130, U.S.

Attention: Kyle Gano

Dear Kyle,

Re: License and Collaboration Agreement between Xenon Pharmaceuticals Inc. (“Xenon”) and Neurocrine Biosciences, Inc. (“Neurocrine”) made as of December 2, 2019, as previously amended (the “Agreement”)

Further to our recent discussions and in accordance with Section 14.8 of the Agreement, and in consideration of the premises and mutual covenants contained herein, Xenon and Neurocrine agree as follows:

Except as specifically defined below, capitalized terms used in this Letter Amendment #2 shall have the same meaning as ascribed to such terms in the Agreement.

“Pain Field means treating the following diseases with a compound whose primary mechanism is NaV1.6 modulation and it binds to and modulates NaV1.7 with an IC50 of 1microM or less: pain indications and pain associated with other diseases or conditions.

“(c) Restriction. Neurocrine shall not, directly or indirectly, Develop, seek Regulatory Approval for, market or promote any Excluded Compound.”

“Third Party Payment Obligations. Subject to Section 8.7(e)(ii) and Section 9.6, each Party shall be responsible for the payment of royalty, milestone and other payments due to Third Parties under any agreements between such Party (or its Affiliates) and Third Parties on account of Neurocrine’s and its Affiliates’ and sublicensees’ Development, manufacture and Commercialization of Products in the Field in the Territory. Without limiting the foregoing, Xenon shall be solely responsible for all payments due under the Genentech License; provided, however, that Neurocrine will, in addition to the applicable royalty rate, pay to Xenon [***] of all payments due under the Genentech License on any Net Sales of Products containing an Early Compound for which the package insert includes at least one category of pain covered under the definition of the Pain Field. In the event that Xenon has failed to make any payment on account of Neurocrine’s or its Affiliate’s or sublicensee’s sale of any Product when due under the Genentech License, and has failed to cure such non-payment within the applicable cure period under the Genentech License, Xenon will provide notice to Neurocrine at least [***] days prior the end of the applicable cure period and Neurocrine shall have the right, but no obligation, to pay any such royalties directly to Genentech and to deduct any such royalties paid to Genentech against any payments to Xenon under this Agreement.”

By the signatures below, the Parties have caused this Letter Amendment #2 to be executed by their respective duly authorized officers to be effective as of the date of this Amendment #2.

Sincerely,

Xenon Pharmaceuticals Inc.

Neurocrine Biosciences, Inc.